Welcome to our dedicated page for Biomerica news (Ticker: BMRA), a resource for investors and traders seeking the latest updates and insights on Biomerica stock.
Biomerica reports developments in diagnostic-guided therapies and medical diagnostic products used in point-of-care, home, physician-office and clinical laboratory settings. The company focuses on gastrointestinal and inflammatory diseases, with recurring updates around inFoods® IBS, a finger-stick blood test used to identify individual food triggers for IBS dietary guidance, and Hp Detect™/hp+detect™, an H. pylori stool antigen diagnostic.
Biomerica news also covers commercialization and regulatory activity for products such as EZ Detect™, an at-home colorectal disease screening test, along with international distribution, laboratory partnerships, reimbursement and coding updates, clinical data presentations, fiscal results and the company’s CDMO services activity.
Biomerica, Inc. (NASDAQ: BMRA) received regulatory clearances from the Kingdom of Saudi Arabia and UAE for two health products: the EZ Detect™ Colon Disease Test and the Aware® Breast Self Exam. These products will be launched through distribution partners in the Middle East and North Africa, targeting areas with high unmet needs. The EZ Detect test allows at-home screening for colorectal cancer, while the Aware device enhances breast cancer detection through self-exams. The company emphasizes the importance of accessible screening in improving health outcomes.
Biomerica (NASDAQ: BMRA) announced that its InFoods® IBS clinical study data received the prestigious ACG Presidential Award at the 2022 Annual Scientific Meeting.
The study highlighted significant improvements in IBS symptoms, such as abdominal pain intensity, outperforming some existing drugs.
With no reported adverse effects, the findings were published in respected medical outlets, enhancing the visibility of InFoods® IBS as a revolutionary approach to managing IBS symptoms, potentially impacting treatment protocols.
Biomerica, Inc. (NASDAQ: BMRA) announces a partnership with Walmart for the Aware® Breast Self Exam device, now available in over 2400 stores. This FDA-cleared device enhances sensitivity for self-exams, crucial for early breast cancer detection, which significantly improves survival rates. The product, retailing at $19.95, is expected to boost visibility and accessibility for women. CEO Zack Irani emphasized the importance of early detection and the role of their product in cancer survival. Discussions for further distribution partnerships are ongoing.
Biomerica, Inc. (BMRA) reported a 30% increase in net sales for Q3 2022, totaling $1.67 million compared to $1.26 million in the previous year. However, the company experienced a net loss of $2 million, or $0.16 per share, up from a $1.5 million loss the prior year. This loss is attributed to increased expenses, including higher salaries and legal fees. The company received patent allowances in Australia and Japan for its InFoods® Technology, which treats ADD/ADHD and depression, respectively. Biomerica aims to launch multiple products by year-end 2022, including an IBS test and an H. Pylori product.
Biomerica (NASDAQ: BMRA) recently announced that its Aware® Breast Self Exam device and EZ Detect™ Colon Disease test are now available on Amazon. The Aware® device enhances tactile sensitivity for breast self-exams, crucial for early detection of breast cancer, the most common cancer among women. Meanwhile, EZ Detect™ is a two-minute test for hidden blood in stool, an early sign of colorectal cancer. Increased availability on Amazon may enhance sales potential, addressing critical health issues with innovative home testing solutions.
Biomerica, Inc. (Nasdaq: BMRA) announced the upcoming launch of its InFoods® IBS test, expected before the end of 2022. This test will be offered through a CLIA-certified laboratory as a laboratory developed test (LDT). Following successful clinical trials at notable centers like Mayo Clinic, there is significant interest from gastroenterologists. Robert Carlson has been appointed Chief Commercial Officer to oversee the launch and commercialization strategy, aiming for national reimbursement and FDA authorization. Revenues from the InFoods IBS test are anticipated before year-end 2022.
Biomerica, Inc. (Nasdaq: BMRA) reported a remarkable 162% increase in revenues for fiscal 2022, totaling $18.9 million, compared to $7.2 million in fiscal 2021. The net loss also improved to $4.6 million from $7.5 million year-over-year. Significant sales growth was driven by COVID-19 antigen tests and OTC products. Important milestones include positive clinical trial results for its InFoods® IBS product, six new patents granted, and successful completion of clinical studies for its H. pylori diagnostic test, with FDA clearance anticipated.
Biomerica, Inc. (BMRA) announced that its Aware® Breast Self Exam device will be available in Walmart stores and online, enhancing early breast cancer detection. The Aware® device, FDA-cleared, helps women increase sensitivity during self-exams, crucial since 80% of breast cancers are detected by women themselves. Walmart's extensive distribution network will boost visibility. Studies indicate the device is effective in detecting early breast changes. The product rollout aims to empower women with health management tools and facilitate monthly self-examinations.
Biomerica Inc. (NASDAQ: BMRA) announced participation in the 2022 BTIG Biotechnology Conference on August 8-9 in New York City. The CEO will engage in one-on-one meetings at the event. Biomerica specializes in biomedical technologies, developing diagnostic and therapeutic products for gastrointestinal and inflammatory diseases. Their offerings aim to improve health outcomes while reducing healthcare costs.
Biomerica, Inc. (BMRA) announced that its hp+detect™ diagnostic test for Helicobacter pylori has received the CE Mark, allowing commercialization in the European Union and other international markets. This test identifies H. pylori, a significant cause of gastric cancer, affecting 45% of the population in Europe's largest countries. CEO Zack Irani confirmed plans to market the product while awaiting FDA clearance for U.S. sales. The CE Mark represents a critical step in expanding Biomerica's reach in the diagnostics market.